On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

J&J and Legend’s first DTC commercial for Carvykti underscores the emotional toll multiple myeloma patients face when they ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

A new combination treatment may offer a promising option for patients with relapsed or refractory cutaneous T-cell lymphoma ...

Prescient Therapeutics (ASX:PTX) has topped up its $6.9 million SPP with a $3 million placement to accelerate its oncology ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition ...

PURPOSEOutcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy ...